Allergan INC (Formerly Actavis INC )

Pharmaceutical manufacturer specializing in generic, brand and biosimilar products.

Based in DC

🤖

AI Overview

With $520K in lobbying spend across 10 quarterly filings, Allergan INC (Formerly Actavis INC ) is an active lobbying client. Their lobbying covers 5 issue areas. Active from 2018 to 2020.

$520K
Total Spend
3
Years Active
1
Firms Hired
2
Lobbyists Deployed
5
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$200K
2019$200K
2020$120K

Issues Lobbied

Lobbying Firms

Lobbyists

Government Agencies Targeted

These are the government entities that Allergan INC (Formerly Actavis INC ) disclosed contacting in their lobbying filings.

HOUSE OF REPRESENTATIVESSENATEWhite House OfficeOffice of Management & Budget (OMB)
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Copyright/Patent, Taxation, Health Issues, Budget/Appropriations

Monitor issues concerning bioequivalence standards for pharmaceuticals.

Advocate for Inter Partes Review (IPR) reform concerning pharmaceuticals.

Monitor technical corrections to H.R. 1, the Tax Cuts and Jobs Act.

Advocate for voluntary best practices related to pharmaceutical pricing. Engage with policymakers on Medicare Part D prescription drug benefit as related to HR 1892, the Bipartisan Budget Act of 2018.

Advocate for FDA oversight of compounded medicines as related to the HR 1625, the Consolidated Appropriations Act of 2018.

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.